Proxy-Reported Quality of Life and Access to Nusinersen Among Patients with Spinal Muscular Atrophy in Saudi Arabia.
Yazed Sulaiman H Al-RuthiaGhadah S AlmuaythirHala H AlrasheedWejdan R AlsharifMohammad-Hani TemsahFahad AlsohimeIbrahim A SalesMonira AlwhaibiFahad A BashiriPublished in: Patient preference and adherence (2021)
The results of this study highlight the uncertainty about the impact of nusinersen on SMA patients' HRQoL. Therefore, the impact of nusinersen on HRQoL should be examined using more robust study designs.